Prothya Biosolutions
26
1
3
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
19.2%
5 terminated/withdrawn out of 26 trials
76.2%
-10.3% vs industry average
54%
14 trials in Phase 3/4
0%
0 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Add-on Intravenous Immunoglobulins in Early Myositis
Role: collaborator
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Role: collaborator
Apotransferrin in Atransferrinemia
Role: lead
Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation
Role: lead
Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery
Role: lead
Apotransferrin in Patients With β-thalassemia
Role: lead
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
Role: collaborator
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Role: collaborator
C1-inhibitor in Allergic ASThma Patients
Role: collaborator
Pharmacokinetics of New HepBQuin
Role: lead
Data Registry of Auto Immune Hemolytic Anemia
Role: collaborator
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Role: collaborator
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
Role: collaborator
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
Role: lead
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
Role: lead
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
Role: lead
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
Role: collaborator
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
Role: collaborator
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
Role: lead
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
Role: lead